Baseline characteristics and safety of a cohort of patients with chronic lymphocytic lymphoma and small lymphocytic lymphoma treated with idelalisib in combination with rituximab: An early access program

Trial Profile

Baseline characteristics and safety of a cohort of patients with chronic lymphocytic lymphoma and small lymphocytic lymphoma treated with idelalisib in combination with rituximab: An early access program

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Sep 2016

At a glance

  • Drugs Idelalisib (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top